Page last updated: 2024-11-12

jte 013

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

JTE 013: an Edg-5 antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

JTE-013 : A semicarbazide derivative that is semicarbazide in which the amino group at position 2 is replaced by a [1,3-dimethyl-4-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridin-6-yl]amino group and the amino group adjacent to the carbonyl is replaced by a (2,6-dichloropyridin-4-yl)amino group. It is a potent S1P2 antagonist (IC50 = 17.6 nM). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID10223146
CHEMBL ID1368758
CHEBI ID92763
SCHEMBL ID5911940
MeSH IDM0446833

Synonyms (35)

Synonym
HMS3269A03
BRD-K43330982-001-01-5
3-(2,6-dichloropyridin-4-yl)-1-[(1,3-dimethyl-4-propan-2-ylpyrazolo[4,5-e]pyridin-6-yl)amino]urea
gtpl2917
NCGC00159556-01
jte-013
jte 013
383150-41-2
S7182
SCHEMBL5911940
n-(2,6-dichloropyridin-4-yl)-2-(4-isopropyl-1,3-dimethyl-1h-pyrazolo[3,4-b]pyridin-6-yl)hydrazinecarboxamide
CHEMBL1368758 ,
AC-32744
AKOS024457073
HMS3650O12
DTXSID60436982
bdbm50065628
1-(2,6-dichloropyridin-4-yl)-3-[(1,3-dimethyl-4-propan-2-ylpyrazolo[3,4-b]pyridin-6-yl)amino]urea
CHEBI:92763
n-(2,6-dichloropyridin-4-yl)-2-(4-isopropyl-1,3-dimethyl-1h-pyrazolo[3,4-b]pyridin-6-yl)hydrazine-1-carboxamide
EX-A2517
HMS3677I20
AS-16377
sr-01000946313
SR-01000946313-1
HMS3413I20
cid 10223146
n-(2,6-dichloro-4-pyridinyl)-2-[1,3-dimethyl-4-(1-methylethyl)-1h-pyrazolo[3,4-b]pyridin-6-yl]-hydrazinecarboxamide
HMS3742I13
CCG-268739
D80459
CS-0019914
HY-100675
1-[1,3-dimethyl-4-(2-methylethyl)-1h-pyrazolo[3,4-b]pyridin-6-yl]-4-(2,6-dichloro-4-pyridinyl)-semicarbazide
A899647

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" To investigate the role of S1P in the development of microvascular permeability and peritubular capillary hypoperfusion in the kidney during CLP-induced AKI, we used a pharmacologic approach and a clinically relevant delayed dosing paradigm."( Pharmacologic targeting of sphingosine-1-phosphate receptor 1 improves the renal microcirculation during sepsis in the mouse.
Gokden, N; Mayeux, PR; Patil, NK; Sims, CR; Wang, Z, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
sphingosine-1-phosphate receptor 2 antagonistAny sphingosine-1-phosphate receptor (S1PR) antagonist that acts as an antagonist for the subtype 2 receptors (S1PR2).
anti-inflammatory agentAny compound that has anti-inflammatory effects.
pro-angiogenic agentAny compound that promotes the growth of new blood vessels from pre-existing vessels.
osteogenesis regulatorAny compound that induces or regulates osteogenesis.
anti-asthmatic agentAny compound that has anti-asthmatic effects.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
chloropyridineCompounds containing a pyridine nucleus substituted with one or more chlorine atoms.
pyrazolopyridine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency19.95260.035520.977089.1251AID504332
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency22.38720.354828.065989.1251AID504847
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency15.84890.00798.23321,122.0200AID2546
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sphingosine 1-phosphate receptor 2Homo sapiens (human)IC50 (µMol)0.04010.00020.10421.1000AID1193521; AID1370457; AID1405275; AID1588466; AID1823962; AID1896055
Sphingosine 1-phosphate receptor 4Homo sapiens (human)IC50 (µMol)1.00000.00100.10680.4170AID1588469
Sphingosine 1-phosphate receptor 1Homo sapiens (human)IC50 (µMol)1.00000.00000.08550.8400AID1370458; AID1588467
Sphingosine 1-phosphate receptor 2Rattus norvegicus (Norway rat)IC50 (µMol)0.02000.02000.02000.0200AID1405276
Sphingosine 1-phosphate receptor 3Homo sapiens (human)IC50 (µMol)1.00000.00000.00450.0230AID1370459; AID1588468
Sphingosine 1-phosphate receptor 5Homo sapiens (human)IC50 (µMol)1.00000.00050.83884.6000AID1588470
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sphingosine 1-phosphate receptor 2Homo sapiens (human)Kd1.96001.96001.96001.9600AID1865783
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sphingosine 1-phosphate receptor 2Homo sapiens (human)Activity1.75001.75001.75001.7500AID1865794
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (45)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathwaySphingosine 1-phosphate receptor 2Homo sapiens (human)
sphingosine-1-phosphate receptor signaling pathwaySphingosine 1-phosphate receptor 2Homo sapiens (human)
positive regulation of cell population proliferationSphingosine 1-phosphate receptor 2Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylationSphingosine 1-phosphate receptor 2Homo sapiens (human)
actin cytoskeleton organizationSphingosine 1-phosphate receptor 2Homo sapiens (human)
filopodium assemblySphingosine 1-phosphate receptor 2Homo sapiens (human)
excitatory postsynaptic potentialSphingosine 1-phosphate receptor 2Homo sapiens (human)
negative regulation of excitatory postsynaptic potentialSphingosine 1-phosphate receptor 2Homo sapiens (human)
positive regulation of establishment of endothelial barrierSphingosine 1-phosphate receptor 2Homo sapiens (human)
regulation of metabolic processSphingosine 1-phosphate receptor 2Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwaySphingosine 1-phosphate receptor 2Homo sapiens (human)
sphingosine-1-phosphate receptor signaling pathwaySphingosine 1-phosphate receptor 4Homo sapiens (human)
immune responseSphingosine 1-phosphate receptor 4Homo sapiens (human)
G protein-coupled receptor signaling pathwaySphingosine 1-phosphate receptor 4Homo sapiens (human)
activation of phospholipase C activitySphingosine 1-phosphate receptor 4Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationSphingosine 1-phosphate receptor 4Homo sapiens (human)
regulation of metabolic processSphingosine 1-phosphate receptor 4Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwaySphingosine 1-phosphate receptor 4Homo sapiens (human)
blood vessel maturationSphingosine 1-phosphate receptor 1Homo sapiens (human)
cardiac muscle tissue growth involved in heart morphogenesisSphingosine 1-phosphate receptor 1Homo sapiens (human)
sphingosine-1-phosphate receptor signaling pathwaySphingosine 1-phosphate receptor 1Homo sapiens (human)
chemotaxisSphingosine 1-phosphate receptor 1Homo sapiens (human)
cell adhesionSphingosine 1-phosphate receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathwaySphingosine 1-phosphate receptor 1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwaySphingosine 1-phosphate receptor 1Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwaySphingosine 1-phosphate receptor 1Homo sapiens (human)
brain developmentSphingosine 1-phosphate receptor 1Homo sapiens (human)
cell population proliferationSphingosine 1-phosphate receptor 1Homo sapiens (human)
cell migrationSphingosine 1-phosphate receptor 1Homo sapiens (human)
transmission of nerve impulseSphingosine 1-phosphate receptor 1Homo sapiens (human)
lamellipodium assemblySphingosine 1-phosphate receptor 1Homo sapiens (human)
actin cytoskeleton organizationSphingosine 1-phosphate receptor 1Homo sapiens (human)
regulation of cell adhesionSphingosine 1-phosphate receptor 1Homo sapiens (human)
neuron differentiationSphingosine 1-phosphate receptor 1Homo sapiens (human)
positive regulation of cell migrationSphingosine 1-phosphate receptor 1Homo sapiens (human)
regulation of bone mineralizationSphingosine 1-phosphate receptor 1Homo sapiens (human)
leukocyte chemotaxisSphingosine 1-phosphate receptor 1Homo sapiens (human)
regulation of bone resorptionSphingosine 1-phosphate receptor 1Homo sapiens (human)
endothelial cell differentiationSphingosine 1-phosphate receptor 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IISphingosine 1-phosphate receptor 1Homo sapiens (human)
positive regulation of smooth muscle cell proliferationSphingosine 1-phosphate receptor 1Homo sapiens (human)
positive regulation of positive chemotaxisSphingosine 1-phosphate receptor 1Homo sapiens (human)
negative regulation of stress fiber assemblySphingosine 1-phosphate receptor 1Homo sapiens (human)
heart trabecula morphogenesisSphingosine 1-phosphate receptor 1Homo sapiens (human)
T cell migrationSphingosine 1-phosphate receptor 1Homo sapiens (human)
angiogenesisSphingosine 1-phosphate receptor 1Homo sapiens (human)
regulation of metabolic processSphingosine 1-phosphate receptor 1Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwaySphingosine 1-phosphate receptor 1Homo sapiens (human)
sphingosine-1-phosphate receptor signaling pathwaySphingosine 1-phosphate receptor 3Homo sapiens (human)
inflammatory responseSphingosine 1-phosphate receptor 3Homo sapiens (human)
G protein-coupled receptor signaling pathwaySphingosine 1-phosphate receptor 3Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwaySphingosine 1-phosphate receptor 3Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationSphingosine 1-phosphate receptor 3Homo sapiens (human)
Notch signaling pathwaySphingosine 1-phosphate receptor 3Homo sapiens (human)
positive regulation of cell population proliferationSphingosine 1-phosphate receptor 3Homo sapiens (human)
anatomical structure morphogenesisSphingosine 1-phosphate receptor 3Homo sapiens (human)
regulation of interleukin-1 beta productionSphingosine 1-phosphate receptor 3Homo sapiens (human)
negative regulation of establishment of endothelial barrierSphingosine 1-phosphate receptor 3Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwaySphingosine 1-phosphate receptor 3Homo sapiens (human)
regulation of metabolic processSphingosine 1-phosphate receptor 3Homo sapiens (human)
sphingosine-1-phosphate receptor signaling pathwaySphingosine 1-phosphate receptor 5Homo sapiens (human)
regulation of neuron differentiationSphingosine 1-phosphate receptor 5Homo sapiens (human)
regulation of metabolic processSphingosine 1-phosphate receptor 5Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwaySphingosine 1-phosphate receptor 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
G protein-coupled receptor bindingSphingosine 1-phosphate receptor 2Homo sapiens (human)
G protein-coupled receptor activitySphingosine 1-phosphate receptor 2Homo sapiens (human)
integrin bindingSphingosine 1-phosphate receptor 2Homo sapiens (human)
protein bindingSphingosine 1-phosphate receptor 2Homo sapiens (human)
lipid bindingSphingosine 1-phosphate receptor 2Homo sapiens (human)
G protein-coupled peptide receptor activitySphingosine 1-phosphate receptor 2Homo sapiens (human)
sphingosine-1-phosphate receptor activitySphingosine 1-phosphate receptor 2Homo sapiens (human)
protein bindingSphingosine 1-phosphate receptor 4Homo sapiens (human)
lipid bindingSphingosine 1-phosphate receptor 4Homo sapiens (human)
sphingosine-1-phosphate receptor activitySphingosine 1-phosphate receptor 4Homo sapiens (human)
G protein-coupled receptor activitySphingosine 1-phosphate receptor 4Homo sapiens (human)
G protein-coupled receptor bindingSphingosine 1-phosphate receptor 1Homo sapiens (human)
G protein-coupled receptor activitySphingosine 1-phosphate receptor 1Homo sapiens (human)
protein bindingSphingosine 1-phosphate receptor 1Homo sapiens (human)
sphingosine-1-phosphate receptor activitySphingosine 1-phosphate receptor 1Homo sapiens (human)
sphingolipid bindingSphingosine 1-phosphate receptor 1Homo sapiens (human)
integrin bindingSphingosine 1-phosphate receptor 3Homo sapiens (human)
protein bindingSphingosine 1-phosphate receptor 3Homo sapiens (human)
lipid bindingSphingosine 1-phosphate receptor 3Homo sapiens (human)
sphingosine-1-phosphate receptor activitySphingosine 1-phosphate receptor 3Homo sapiens (human)
G protein-coupled receptor activitySphingosine 1-phosphate receptor 3Homo sapiens (human)
protein bindingSphingosine 1-phosphate receptor 5Homo sapiens (human)
sphingosine-1-phosphate receptor activitySphingosine 1-phosphate receptor 5Homo sapiens (human)
G protein-coupled receptor activitySphingosine 1-phosphate receptor 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
plasma membraneSphingosine 1-phosphate receptor 2Homo sapiens (human)
postsynapseSphingosine 1-phosphate receptor 2Homo sapiens (human)
plasma membraneSphingosine 1-phosphate receptor 2Homo sapiens (human)
cytoplasmSphingosine 1-phosphate receptor 2Homo sapiens (human)
mitochondrionSphingosine 1-phosphate receptor 4Homo sapiens (human)
plasma membraneSphingosine 1-phosphate receptor 4Homo sapiens (human)
plasma membraneSphingosine 1-phosphate receptor 4Homo sapiens (human)
cytoplasmSphingosine 1-phosphate receptor 4Homo sapiens (human)
nucleoplasmSphingosine 1-phosphate receptor 1Homo sapiens (human)
endosomeSphingosine 1-phosphate receptor 1Homo sapiens (human)
plasma membraneSphingosine 1-phosphate receptor 1Homo sapiens (human)
external side of plasma membraneSphingosine 1-phosphate receptor 1Homo sapiens (human)
intracellular membrane-bounded organelleSphingosine 1-phosphate receptor 1Homo sapiens (human)
membrane raftSphingosine 1-phosphate receptor 1Homo sapiens (human)
plasma membraneSphingosine 1-phosphate receptor 1Homo sapiens (human)
cytoplasmSphingosine 1-phosphate receptor 1Homo sapiens (human)
plasma membraneSphingosine 1-phosphate receptor 3Homo sapiens (human)
cytoplasmSphingosine 1-phosphate receptor 3Homo sapiens (human)
plasma membraneSphingosine 1-phosphate receptor 3Homo sapiens (human)
plasma membraneSphingosine 1-phosphate receptor 5Homo sapiens (human)
cytoplasmSphingosine 1-phosphate receptor 5Homo sapiens (human)
plasma membraneSphingosine 1-phosphate receptor 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (58)

Assay IDTitleYearJournalArticle
AID1784329AUC (0 to t) in Sprague-Dawley rat plasma at 1 mg/kg, iv measured for 24 hrs by LC-MS/MS analysis2021European journal of medicinal chemistry, Dec-05, Volume: 225Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
AID1784330AUC (0 to infinity) in Sprague-Dawley rat blood at 1 mg/kg, iv by LC-MS/MS analysis2021European journal of medicinal chemistry, Dec-05, Volume: 225Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
AID1784296Initial drug concentration in Sprague-Dawley rat blood at 1 mg/kg, iv by LC-MS/MS analysis2021European journal of medicinal chemistry, Dec-05, Volume: 225Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
AID1405275Antagonist activity at human S1P2 receptor2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Fibrogenic Disorders in Human Diseases: From Inflammation to Organ Dysfunction.
AID1784340Drug concentration in Sprague-Dawley rat blood at 1 mg/kg, iv measured after 8 hrs by LC-MS/MS analysis2021European journal of medicinal chemistry, Dec-05, Volume: 225Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
AID1405276Antagonist activity at rat S1P2 receptor2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Fibrogenic Disorders in Human Diseases: From Inflammation to Organ Dysfunction.
AID1784314Reversal of 5-FU resistance against human SW620/5-FU cells assessed as inhibition of cell proliferation measured after 72 hrs in presence of 5-FU by MTT assay2021European journal of medicinal chemistry, Dec-05, Volume: 225Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
AID1784323Antagonist activity at S1PR2 in human SW620/5-FU cells assessed as reduction of DPD-catalyzed 5-FU degradation by measuring intracellular 5-FU level at 2 uM measured after 6 hrs by HPLC-UV analysis (Rvb = 0.59 mg/L)2021European journal of medicinal chemistry, Dec-05, Volume: 225Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
AID1784335Clearance in Sprague-Dawley rat plasma at 1 mg/kg, iv measured for 24 hrs by LC-MS/MS analysis2021European journal of medicinal chemistry, Dec-05, Volume: 225Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
AID1588466Displacement of [32P]S1P from recombinant human S1PR2 expressed in commercial cell membranes incubated for 60 mins by scintillation counting method2019Bioorganic & medicinal chemistry, 08-15, Volume: 27, Issue:16
Design, synthesis, and in vitro bioactivity evaluation of fluorine-containing analogues for sphingosine-1-phosphate 2 receptor.
AID1784315Reversal of 5-FU resistance against human HCT-116 cells overexpressing DPD assessed as inhibition of cell proliferation measured after 72 hrs in presence of 5-FU by MTT assay2021European journal of medicinal chemistry, Dec-05, Volume: 225Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
AID1784324Antagonist activity at S1PR2 in human SW620/5-FU cells assessed as reduction of DPD-catalyzed 5-FU degradation by measuring intracellular FBAL level at 2 uM measured after 6 hrs by HPLC-UV analysis (Rvb = 2.88 mg/L)2021European journal of medicinal chemistry, Dec-05, Volume: 225Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
AID1370459Displacement of [32P]S1P from recombinant human S1PR3 expressed in Chem1 cell membranes co-expressing Galpha15 pretreated for 30 mins followed by [32P]S1P addition measured after 60 mins by scintillation counting method2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Design and synthesis of pyrazolopyridine derivatives as sphingosine 1-phosphate receptor 2 ligands.
AID1784338Mean residence time (0 to infinity) in Sprague-Dawley rat blood at 1 mg/kg, iv by LC-MS/MS analysis2021European journal of medicinal chemistry, Dec-05, Volume: 225Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
AID1588468Displacement of [32P]S1P from recombinant human S1PR3 expressed in commercial cell membranes incubated for 60 mins by scintillation counting method2019Bioorganic & medicinal chemistry, 08-15, Volume: 27, Issue:16
Design, synthesis, and in vitro bioactivity evaluation of fluorine-containing analogues for sphingosine-1-phosphate 2 receptor.
AID1784297Initial plasma concentration in Sprague-Dawley rat at 1 mg/kg, iv by LC-MS/MS analysis2021European journal of medicinal chemistry, Dec-05, Volume: 225Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
AID1784334Clearance in Sprague-Dawley rat blood at 1 mg/kg, iv measured for 24 hrs by LC-MS/MS analysis2021European journal of medicinal chemistry, Dec-05, Volume: 225Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
AID1784337Mean residence time (0 to t) in Sprague-Dawley rat plasma at 1 mg/kg, iv measured for 24 hrs by LC-MS/MS analysis2021European journal of medicinal chemistry, Dec-05, Volume: 225Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
AID1370457Displacement of [32P]S1P from recombinant human S1PR2 expressed in Chem1 cell membranes co-expressing Galpha15 pretreated for 30 mins followed by [32P]S1P addition measured after 60 mins by scintillation counting method2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Design and synthesis of pyrazolopyridine derivatives as sphingosine 1-phosphate receptor 2 ligands.
AID1865784Reversal of 5-FU resistance against 5-FU resistant DPD expressed human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs in presence of 5-FU by MTT assay
AID1370458Displacement of [32P]S1P from recombinant human S1PR1 expressed in CHOK1 cell membranes pretreated for 30 mins followed by [32P]S1P addition measured after 60 mins by scintillation counting method2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Design and synthesis of pyrazolopyridine derivatives as sphingosine 1-phosphate receptor 2 ligands.
AID1784339Mean residence time (0 to infinity) in Sprague-Dawley rat plasma at 1 mg/kg, iv by LC-MS/MS analysis2021European journal of medicinal chemistry, Dec-05, Volume: 225Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
AID1370460Displacement of [32P]S1P from recombinant human S1PR4 expressed in cell membranes pretreated for 30 mins followed by [32P]S1P addition measured after 60 mins by scintillation counting method2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Design and synthesis of pyrazolopyridine derivatives as sphingosine 1-phosphate receptor 2 ligands.
AID1588470Displacement of [32P]S1P from recombinant human S1PR5 expressed in commercial cell membranes incubated for 60 mins by scintillation counting method2019Bioorganic & medicinal chemistry, 08-15, Volume: 27, Issue:16
Design, synthesis, and in vitro bioactivity evaluation of fluorine-containing analogues for sphingosine-1-phosphate 2 receptor.
AID1784298Toxicity in athymic nude mouse xenografted with human SW620/5-FU cells assessed as histopathological changes in liver at 12.5 mg/kg/day, iv administered for 24 days in presence of 5-FU and measured on day 24 by immunohistochemistry2021European journal of medicinal chemistry, Dec-05, Volume: 225Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
AID1784307Reversal of 5-FU resistance against human SW620/5-FU cells xenografted in athymic nude mouse assessed as potentiation of 5-FU induced antitumor activity by measuring inhibition of tumor growth at 12.5 mg/kg/day, iv administered for 24 days in presence of 2021European journal of medicinal chemistry, Dec-05, Volume: 225Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
AID1865794Antagonist activity at S1PR2 in human SW620/5-FU cells assessed as reduction of DPD-catalyzed 5-FU degradation by measuring intracellular 5-FU level at 20 uM measured after 24 hrs by HPLC-UV analysis (Rvb = 2.57 uM)
AID1784294AUC (0 to t) in Sprague-Dawley rat blood at 1 mg/kg, iv measured for 24 hrs by LC-MS/MS analysis2021European journal of medicinal chemistry, Dec-05, Volume: 225Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
AID1588469Displacement of [32P]S1P from recombinant human S1PR4 expressed in commercial cell membranes incubated for 60 mins by scintillation counting method2019Bioorganic & medicinal chemistry, 08-15, Volume: 27, Issue:16
Design, synthesis, and in vitro bioactivity evaluation of fluorine-containing analogues for sphingosine-1-phosphate 2 receptor.
AID1784336Mean residence time (0 to t) in Sprague-Dawley rat blood at 1 mg/kg, iv measured for 24 hrs by LC-MS/MS analysis2021European journal of medicinal chemistry, Dec-05, Volume: 225Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
AID1865785Reversal of 5-FU resistance against human SW620/5-FU cells assessed as reduction in cell viability incubated for 48 hrs in presence of 5-FU by MTT assay
AID1784328Half life in Sprague-Dawley rat plasma at 1 mg/kg, iv measured for 24 hrs by LC-MS/MS analysis2021European journal of medicinal chemistry, Dec-05, Volume: 225Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
AID1370461Displacement of [32P]S1P from recombinant human S1PR5 expressed in cell membranes pretreated for 30 mins followed by [32P]S1P addition measured after 60 mins by scintillation counting method2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Design and synthesis of pyrazolopyridine derivatives as sphingosine 1-phosphate receptor 2 ligands.
AID1784299Downregulation of DPD expression in liver of athymic nude mouse xenografted with human SW620/5-FU at 12.5 mg/kg/day, iv administered for 24 days in presence of 5-FU and measured on day 24 by immunohistochemistry2021European journal of medicinal chemistry, Dec-05, Volume: 225Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
AID1784309Toxicity in athymic nude mouse xenografted with human SW620/5-FU cells assessed as body weight loss at 12.5 mg/kg/day, iv administered for 24 days in presence of 5-FU and measured after 12 days2021European journal of medicinal chemistry, Dec-05, Volume: 225Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
AID1784312Binding affinity to S1PR2 (unknown origin) assessed as dissociation constant measured for 60 secs by surface plasmon resonance assay2021European journal of medicinal chemistry, Dec-05, Volume: 225Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
AID1784344Downregulation of DPD expression in colon of athymic nude mouse xenografted with human SW620/5-FU cells at 12.5 mg/kg/day, iv administered for 24 days in presence of 5-FU and measured on day 24 by immunohistochemistry2021European journal of medicinal chemistry, Dec-05, Volume: 225Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
AID1784331AUC (0 to infinity) in Sprague-Dawley rat plasma at 1 mg/kg, iv by LC-MS/MS analysis2021European journal of medicinal chemistry, Dec-05, Volume: 225Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
AID1784311Binding affinity to S1PR2 (unknown origin) assessed as association constant measured for 60 secs by surface plasmon resonance assay2021European journal of medicinal chemistry, Dec-05, Volume: 225Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
AID1784295Half life in Sprague-Dawley rat blood at 1 mg/kg, iv measured for 24 hrs by LC-MS/MS analysis2021European journal of medicinal chemistry, Dec-05, Volume: 225Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
AID1193521Antagonist activity at S1P2 receptor (unknown origin)2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Discovery of novel S1P2 antagonists. Part 1: discovery of 1,3-bis(aryloxy)benzene derivatives.
AID1784342Ratio of drug level in Sprague-Dawley rat blood to plasma at 1 mg/kg, iv measured for 24 hrs by LC-MS/MS analysis2021European journal of medicinal chemistry, Dec-05, Volume: 225Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
AID1784316Cytotoxicity against human NCM460 cells assessed as cell viability measured after 72 hrs in presence of 5-FU by MTT assay2021European journal of medicinal chemistry, Dec-05, Volume: 225Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
AID1865783Binding affinity to S1PR2 (unknown origin) by SPR assay
AID1784313Binding affinity to S1PR2 (unknown origin) measured by surface plasmon resonance assay2021European journal of medicinal chemistry, Dec-05, Volume: 225Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
AID1784332Volume of distribution in Sprague-Dawley rat blood at 1 mg/kg, iv measured for 24 hrs by LC-MS/MS analysis2021European journal of medicinal chemistry, Dec-05, Volume: 225Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
AID1896055Inhibition of S1PR2 (unknown origin)2021Journal of medicinal chemistry, 12-23, Volume: 64, Issue:24
The Repertoire of Small-Molecule PET Probes for Neuroinflammation Imaging: Challenges and Opportunities beyond TSPO.
AID1784300Downregulation of DPD expression in tumour of athymic nude mouse xenografted with human SW620/5-FU at 12.5 mg/kg/day, iv administered for 24 days in presence of 5-FU and measured on day 24 by immunohistochemistry2021European journal of medicinal chemistry, Dec-05, Volume: 225Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
AID1588467Displacement of [32P]S1P from recombinant human S1PR1 expressed in commercial cell membranes incubated for 60 mins by scintillation counting method2019Bioorganic & medicinal chemistry, 08-15, Volume: 27, Issue:16
Design, synthesis, and in vitro bioactivity evaluation of fluorine-containing analogues for sphingosine-1-phosphate 2 receptor.
AID1784333Volume of distribution in Sprague-Dawley rat plasma at 1 mg/kg, iv measured for 24 hrs by LC-MS/MS analysis2021European journal of medicinal chemistry, Dec-05, Volume: 225Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
AID1784341Plasma concentration in Sprague-Dawley rat at 1 mg/kg, iv measured after 8 hrs by LC-MS/MS analysis2021European journal of medicinal chemistry, Dec-05, Volume: 225Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
AID1823962Antagonist activity at S1P2 (unknown origin)
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1346223Rat S1P2 receptor (Lysophospholipid (S1P) receptors)2002Biochemical and biophysical research communications, Dec-06, Volume: 299, Issue:3
Enhancement of sphingosine 1-phosphate-induced migration of vascular endothelial cells and smooth muscle cells by an EDG-5 antagonist.
AID1346236Human S1P2 receptor (Lysophospholipid (S1P) receptors)2002Biochemical and biophysical research communications, Dec-06, Volume: 299, Issue:3
Enhancement of sphingosine 1-phosphate-induced migration of vascular endothelial cells and smooth muscle cells by an EDG-5 antagonist.
AID1346223Rat S1P2 receptor (Lysophospholipid (S1P) receptors)2003Gastroenterology, Feb, Volume: 124, Issue:2
Antiproliferative property of sphingosine 1-phosphate in rat hepatocytes involves activation of Rho via Edg-5.
AID1345463Human P2RY10 (Class A Orphans)2008Biochemical and biophysical research communications, Jul-11, Volume: 371, Issue:4
Identification of the orphan GPCR, P2Y(10) receptor as the sphingosine-1-phosphate and lysophosphatidic acid receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (84)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's16 (19.05)29.6817
2010's53 (63.10)24.3611
2020's15 (17.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.73

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.73 (24.57)
Research Supply Index4.44 (2.92)
Research Growth Index4.84 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.73)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (4.76%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other80 (95.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]